AUPH vs. VKTX, AXSM, TGTX, KRYS, OGN, RARE, ADMA, SRRK, ALVO, and VRNA
Should you be buying Aurinia Pharmaceuticals stock or one of its competitors? The main competitors of Aurinia Pharmaceuticals include Viking Therapeutics (VKTX), Axsome Therapeutics (AXSM), TG Therapeutics (TGTX), Krystal Biotech (KRYS), Organon & Co. (OGN), Ultragenyx Pharmaceutical (RARE), ADMA Biologics (ADMA), Scholar Rock (SRRK), Alvotech (ALVO), and Verona Pharma (VRNA). These companies are all part of the "pharmaceutical products" industry.
Aurinia Pharmaceuticals vs.
Aurinia Pharmaceuticals (NASDAQ:AUPH) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, community ranking, valuation, risk, media sentiment and analyst recommendations.
36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 4.3% of Aurinia Pharmaceuticals shares are owned by insiders. Comparatively, 4.7% of Viking Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Viking Therapeutics has a net margin of 0.00% compared to Aurinia Pharmaceuticals' net margin of -10.23%. Aurinia Pharmaceuticals' return on equity of -4.41% beat Viking Therapeutics' return on equity.
Aurinia Pharmaceuticals has higher revenue and earnings than Viking Therapeutics. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Viking Therapeutics had 13 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 14 mentions for Viking Therapeutics and 1 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 0.46 beat Viking Therapeutics' score of 0.29 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.
Aurinia Pharmaceuticals currently has a consensus target price of $10.00, indicating a potential upside of 24.84%. Viking Therapeutics has a consensus target price of $106.75, indicating a potential upside of 226.95%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Viking Therapeutics is more favorable than Aurinia Pharmaceuticals.
Viking Therapeutics received 48 more outperform votes than Aurinia Pharmaceuticals when rated by MarketBeat users. Likewise, 79.92% of users gave Viking Therapeutics an outperform vote while only 73.27% of users gave Aurinia Pharmaceuticals an outperform vote.
Aurinia Pharmaceuticals has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.
Summary
Viking Therapeutics beats Aurinia Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get Aurinia Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aurinia Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:AUPH) was last updated on 1/21/2025 by MarketBeat.com Staff
Free AUPH Stock Alerts